StockData

AbCellera Biologics vs Wave Life Sciences

ABCL and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABCL and WVE compare

AbCellera Biologics is the larger company, worth 5.7 times as much as Wave Life Sciences ($3.5B against $617M).

AbCellera Biologics keeps more of each dollar of sales as profit, with a net margin of −219% compared with −297% at Wave Life Sciences.

Wave Life Sciences scores higher on the StockData Score (10 against 8 for AbCellera Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABCLWVE
Size and price
Market cap$3.5B$617M
Share price$11.49$3.13
Change, 1 year189%−55.0%
Change, 5 years−27.3%−27.4%
Beta (5Y)1.461.30
Employees562317
StockData Score
Total score810 (better)
Valuation score03 (better)
Growth score11
Performance score11
Health score6 (better)5
Dividend score00
Valuation
P/S51.9×8.7× (better)
P/B3.3×1.5× (better)
FCF yield−0.93% (better)−33.8%
Fair value$4.50$5.15
Margin of safety−155%39.2% (better)
Growth
Revenue growth (TTM)92.1%–
Revenue growth, 5Y average−20.3%16.3% (better)
Profitability
Operating margin−298% (better)−321%
Net margin−219% (better)−297%
FCF margin−48.4% (better)−294%
Return on equity−14.6% (better)−80.0%
Return on invested capital−41.7%–
Financial health
Debt / equity0.000.00
Current ratio12.43 (better)8.38
Altman Z-score4.92 (better)−0.98
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions37.9%92.6%
Held by insiders22.8%23.1%
Insider net buying, 12 months$3.2M$66.5M (better)
Superinvestors holding–1
Short interest, % of float12.3%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.